Laura Smith-Cove
Manchester, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Real-world Safety and Effectiveness of Neoadjuvant Chemoimmunotherapy in Squamous Cell Lung Cancer: A Retrospective European Multicenter Study.
Journal: Clinical lung cancer
Published: April 07, 2026
Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapy.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 25, 2025
Multimodality curative-intent treatment in NSCLC: an unprecedented era of change 2017-2025.
Journal: Thorax
Published: February 16, 2025
Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer-final analysis from the phase II PACIFIC-6 trial.
Journal: ESMO open
Published: November 18, 2024
A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 25, 2024
Efficacy of carboplatin-etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis.
Journal: Therapeutic advances in medical oncology
Published: May 20, 2024
Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial.
Journal: The Lancet. Respiratory medicine
Published: November 17, 2023
Experience With the Routine Use of Electronic Patient-Reported Outcome Measures for Patients With Lung Cancer.
Journal: JCO clinical cancer informatics
Published: April 18, 2023
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: May 26, 2022
Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index.
Journal: Targeted oncology
Published: May 05, 2022
The diagnostic pathway in lung cancer patients with best supportive care decisions: are there lessons to be learnt?
Journal: Clinical medicine (London, England)
Published: April 21, 2022
Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma.
Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma.
Journal: JAAD case reports
Published: April 25, 2018
Last Updated: 09/26/2026